Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor + (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane Meeting Abstract
| Authors: | Schwartzberg, L. S.; Bondarenko, I.; Tolaney, S. M.; Seidman, A. D.; O'Shaughnessy, J.; Shparyk, Y. V.; Chung, C. F.; Lu, Y. S.; Chic, N.; Panasci, L. C.; Chae, Y. S.; Recalde, S.; Hotko, Y.; Gomez, P.; Wright, G. L. S.; Dacosta, N. A.; Vatandoust, S.; O'Connell, J. P.; Wei, T.; Rugo, H. S. |
| Abstract Title: | Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor + (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120600166 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.1061 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1061 -- Source: Wos |
